I-Mab Names Raj Kannan as CEO

I-Mab, a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of immunotherapies, appointed Raj Kannan CEO and a member of the board of directors, effective June 22, 2023.

Kannan has more than 30 years of industry experience in creating and developing global specialty medicine franchises as a biotech CEO. Kannan has successfully led blockbuster product launches across several therapeutic areas including oncology both in the U.S. and globally. As the CEO of Aerie Pharmaceuticals, and before that of Chiasma Pharmaceuticals, he delivered significant value to shareholders exiting both companies successfully while increasing the potential reach of approved and candidate medicines. Mr. Kannan’s bio can be found here.

“I am very pleased to welcome Mr. Raj Kannan on board,” said Jingwu Zang, founder and chairman of I-Mab. Raj joins the Company at a critical juncture to strengthen its strategic position as a U.S.-based global company. Raj is a distinguished leader with the global experience and vision to drive sustainable growth and realize the full potential of our differentiated oncology portfolio as we move into our next phase of growth and innovation.”

“It is an exciting time to be joining I-Mab with the Company’s advanced and differentiated clinical assets generating promising clinical data,” said Kannan. “I look forward to working with Dr. Zang and the talented team at I-Mab to further advance the robust pipeline to deliver on the full potential of the portfolio globally.”